In 2002, a large American trial called the Women's Health Initiative (WHI) published results that made international headlines: hormone replacement therapy increased breast cancer risk. Within months, millions of women stopped their prescriptions. Prescribing rates in the US fell by more than 30% within a year.[1]

Twenty years later, the picture looks considerably more complicated. The study examined the wrong population, used a drug combination that most current guidelines no longer recommend as first choice, and reported risk in a way that maximised alarm.

That doesn't mean the concern is baseless. But if you've made a decision about HRT based on 2002 headlines, you may be working with incomplete information.

What the WHI Actually Studied

The Women's Health Initiative was not designed to study perimenopause. It was designed to study whether HRT reduced heart disease in older postmenopausal women.[2] The key facts about the participants:

  • Average age: 63 years[2]
  • Most participants were more than 10 years past their last menstrual period
  • The estrogen used was oral conjugated equine estrogen (CEE, derived from horse urine), not the bioidentical estradiol used in most modern prescriptions
  • The progestogen used was medroxyprogesterone acetate (MPA), a synthetic progestin

The arm that used combined estrogen and MPA (for women who still had a uterus) was the one stopped early. The estrogen-only arm (for women who had had a hysterectomy) was not stopped for breast cancer concerns. In that arm, there was actually a trend toward reduced breast cancer risk.[3]

Absolute vs. Relative Risk

When the results were reported, they used relative risk: HRT users had a "26% increase" in breast cancer risk compared to the placebo group.[2]

Relative risk figures are accurate but context-free. The absolute numbers behind that 26% increase were:

  • Placebo group: 30 breast cancer cases per 10,000 women per year
  • HRT group: 38 breast cancer cases per 10,000 women per year
  • Absolute difference: 8 additional cases per 10,000 women per year

To put that in context: drinking one glass of wine daily is associated with a similar increase in absolute breast cancer risk.[4] The WHI finding was real, but the way it was communicated made it sound catastrophic when the absolute numbers were modest.

The Timing Hypothesis

The most significant development in HRT research since 2002 is what researchers call the "critical window" or "timing hypothesis": the risk-benefit profile of HRT differs substantially depending on when you start it relative to menopause.[5]

Women in the WHI were, on average, 63 when they started treatment. Most had been postmenopausal for more than a decade. Women who start HRT during perimenopause or within 10 years of their final menstrual period appear to have a different experience entirely.

A reanalysis of WHI data published in JAMA Internal Medicine found that for women who started HRT within 10 years of menopause, there was no significant increase in cardiovascular events, and in some subgroups, cardiovascular risk was lower.[6] This is consistent with mechanistic research suggesting that estrogen is cardioprotective in a healthy vascular system but may accelerate existing atherosclerosis in older vessels.[5]

The Danish Nurses' Cohort Study enrolled women at or near the onset of menopause and followed them for 10 years. HRT users had significantly lower rates of heart attack, heart failure, and overall mortality compared to non-users, with no significant difference in breast cancer rates.[7] This was a primary finding from a large, prospective study, not a secondary result.

Which Progestogen Matters

The estrogen-only arm of the WHI did not show increased breast cancer risk. The increase was confined to the combined estrogen-plus-MPA arm.[3]

MPA (medroxyprogesterone acetate) is a synthetic progestin with properties different from the body's natural progesterone. Subsequent research has found that the type of progestogen used alongside estrogen affects breast cancer risk:

  • Synthetic progestins (MPA, norethisterone, levonorgestrel) are associated with a modest increase in breast cancer risk in combined HRT[8]
  • Micronized progesterone (bioidentical, marketed as Utrogestan or Prometrium) appears to carry lower breast cancer risk, though evidence is still accumulating[8]

The E3N cohort study, which followed French women for 8.9 years, found that estrogen combined with micronized progesterone was not associated with increased breast cancer risk, while estrogen combined with synthetic progestins was.[8]

Current UK guidelines (NICE 2023) and the British Menopause Society now recommend micronized progesterone as the preferred progestogen where HRT is indicated.[9]

What Current Guidelines Say

The North American Menopause Society (NAMS), the British Menopause Society (BMS), and the International Menopause Society (IMS) have converged on broadly similar positions:

For healthy women under 60, or within 10 years of menopause, with bothersome symptoms, the benefits of HRT typically outweigh the risks.[9][10] This includes quality of life, symptom control, cardiovascular protection when started early, bone density preservation, and possibly cognitive benefit.

The absolute increase in breast cancer risk associated with HRT is small, varies by duration of use and type of progestogen, and is comparable in magnitude to other lifestyle factors that receive far less attention.[4]

For women with a personal history of hormone-receptor-positive breast cancer, HRT remains contraindicated pending further evidence.[9] For women with a family history, the risk-benefit calculation should be done with an oncologist or menopause specialist.

Your Individual Risk Calculation

The WHI finding was not fabricated. There is a small increase in breast cancer risk associated with combined HRT, particularly with synthetic progestins, in women who use it for five or more years. That is a real consideration.

But the interpretation of that risk, and its communication in 2002, was deeply flawed. The study used the wrong population, the wrong drugs, and reported findings in the most alarming way possible.

If you are in perimenopause, have symptoms that significantly affect your quality of life, and are not in a high-risk category for breast cancer, the evidence supports a real conversation with your doctor about HRT. The question is not "Is HRT safe?" in the abstract. The question is: for you, at your age, with your health history, and with the current formulations available, do the benefits outweigh the risks? That answer is almost always individualized, and frequently yes.

## References [1] Hersh, A. L., Stefanick, M. L., Stafford, R. S. (2004). National use of postmenopausal hormone therapy: Annual trends and response to recent evidence. JAMA, 291(1), 47-53. https://doi.org/10.1001/jama.291.1.47

[2] Rossouw, J. E., Anderson, G. L., Prentice, R. L., et al. (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA, 288(3), 321-333. https://doi.org/10.1001/jama.288.3.321

[3] Anderson, G. L., Limacher, M., Assaf, A. R., et al. (2004). Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA, 291(14), 1701-1712. https://doi.org/10.1001/jama.291.14.1701

[4] Allen, N. E., Beral, V., Casabonne, D., et al. (2009). Moderate alcohol intake and cancer incidence in women. Journal of the National Cancer Institute, 101(5), 296-305. https://doi.org/10.1093/jnci/djn514

[5] Manson, J. E., Clarkson, T. B., Karas, R. H. (2006). Effects of conjugated equine estrogen on the cardiovascular system: Findings from the Women's Health Initiative. Arteriosclerosis, Thrombosis, and Vascular Biology, 26(8), 1700-1707.

[6] Manson, J. E., Chlebowski, R. T., Stefanick, M. L., et al. (2013). Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA, 310(13), 1353-1368. https://doi.org/10.1001/jama.2013.278040

[7] Schierbeck, L. L., Rejnmark, L., Tofteng, C. L., et al. (2012). Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ, 345, e6409. https://doi.org/10.1136/bmj.e6409

[8] Fournier, A., Berrino, F., Clavel-Chapelon, F. (2008). Unequal risks for breast cancer associated with different hormone replacement therapies: Results from the E3N cohort study. Breast Cancer Research and Treatment, 107(1), 103-111. https://doi.org/10.1007/s10549-007-9523-x

[9] NICE Guideline NG23. (2023). Menopause: Diagnosis and Management. National Institute for Health and Care Excellence. https://www.nice.org.uk/guidance/ng23

[10] The NAMS 2022 Hormone Therapy Position Statement Advisory Panel. (2022). The 2022 hormone therapy position statement of The Menopause Society. Menopause, 29(7), 767-794. https://doi.org/10.1097/GME.0000000000002028